The healthcare supplier raised its organic sales growth projection to 9%-10% but lowered adjusted EBITDA guidance to $3.3B-$3.4B for Q2 2026.
Medline revised its 2026 organic sales growth outlook to 9%-10%, up from prior guidance, following a 12% increase in Q2 2026 revenue. The company cited strong performance in Supply Chain Solutions, which grew 16% due to new customer signings and expansion within existing accounts.
Adjusted EBITDA guidance was lowered to $3.3 billion-$3.4 billion, reflecting operational adjustments. The prior quarter’s growth exceeded expectations, driven by broad-based demand across its business segments.
Management highlighted momentum in core markets but did not disclose immediate market reactions to the revised projections.